MDACC Study No:BTTC11-02 ( NCT No: NCT01266031)
Title:Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus Vorinostat in Adults with Recurrent Glioblastoma
Principal Investigator:Marta Penas-Prado
Treatment Agent:Avastin; Vorinostat
Study Status:Closed
Study Description:The goal of this Phase I portion of this clinical research study is to find the
highest tolerable dose of bevacizumab with or without vorinostat, that can be
given to patients with malignant gliomas. The safety of these drug combinations
will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase I/Phase II
Treatment Agents:Avastin
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Genentech, Inc.
Merck Sharp and Dohme Corp.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Marta Penas-Prado
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults